Limits...
Development and evaluation of a baseline-event-anticipation score for hepatitis delta.

Calle Serrano B, Großhennig A, Homs M, Heidrich B, Erhardt A, Deterding K, Jaroszewicz J, Bremer B, Koch A, Cornberg M, Manns MP, Buti M, Wedemeyer H - J. Viral Hepat. (2014)

Bottom Line: The baseline-event-anticipation score (BEA score) was developed based on variables associated with the development of liver-related clinical complications.Age, region of origin, presence of cirrhosis, albumin, INR, hyperbilirubinemia and thrombocytopenia were all associated with the development of an event in the training cohort.Delta hepatitis is associated with a very severe long-term outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF), Partner Side HepNet Study-House, Hannover, Germany.

Show MeSH

Related in: MedlinePlus

(a) BEA score algorithm. Patients with chronic hepatitis delta receive one point for every single condition met. The baseline-event-anticipation score is calculated by the sum of all points obtained. Patients with a BEA score of 0–1 points are have mild risk of developing an event (BEA-A); those with 2, 3 or 4 points have moderate risk (BEA-B); subjects with five or more points are at high risk (BEA-C) of suffering a major liver-related complication. Note: due to missing values of the different variables, only 59 of the 75 anti-HDV patients were included in this analysis. (b) Receiving operating characteristic (ROC) curves of the BEA score and the three BEA risk categories.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263246&req=5

fig02: (a) BEA score algorithm. Patients with chronic hepatitis delta receive one point for every single condition met. The baseline-event-anticipation score is calculated by the sum of all points obtained. Patients with a BEA score of 0–1 points are have mild risk of developing an event (BEA-A); those with 2, 3 or 4 points have moderate risk (BEA-B); subjects with five or more points are at high risk (BEA-C) of suffering a major liver-related complication. Note: due to missing values of the different variables, only 59 of the 75 anti-HDV patients were included in this analysis. (b) Receiving operating characteristic (ROC) curves of the BEA score and the three BEA risk categories.

Mentions: After the variable selection was finished, we assigned them points according to their hazard ratio (HR): age older than 40 (HR = 2.1, P = 0.04), Eastern Mediterranean origin (HR = 3.76, P < 0.001), INR above 1.2 (HR = 4.56, P < 0.001), platelet count below 100 000/μL (1 point, HR = 6.65, P < 0.001) or 50 000/μL (2 points, HR = 11.63, P < 0.001), bilirubin above the ULN (HR = 2.21, P = 0.04) and male sex (HR = 2.07, P = 0.08) (Table 2, Fig. 2a). Taken together, in the BEA score, we included factors that reflect the patient's demographics, the presence of portal hypertension, and the liver's protein production and breakdown functions.


Development and evaluation of a baseline-event-anticipation score for hepatitis delta.

Calle Serrano B, Großhennig A, Homs M, Heidrich B, Erhardt A, Deterding K, Jaroszewicz J, Bremer B, Koch A, Cornberg M, Manns MP, Buti M, Wedemeyer H - J. Viral Hepat. (2014)

(a) BEA score algorithm. Patients with chronic hepatitis delta receive one point for every single condition met. The baseline-event-anticipation score is calculated by the sum of all points obtained. Patients with a BEA score of 0–1 points are have mild risk of developing an event (BEA-A); those with 2, 3 or 4 points have moderate risk (BEA-B); subjects with five or more points are at high risk (BEA-C) of suffering a major liver-related complication. Note: due to missing values of the different variables, only 59 of the 75 anti-HDV patients were included in this analysis. (b) Receiving operating characteristic (ROC) curves of the BEA score and the three BEA risk categories.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263246&req=5

fig02: (a) BEA score algorithm. Patients with chronic hepatitis delta receive one point for every single condition met. The baseline-event-anticipation score is calculated by the sum of all points obtained. Patients with a BEA score of 0–1 points are have mild risk of developing an event (BEA-A); those with 2, 3 or 4 points have moderate risk (BEA-B); subjects with five or more points are at high risk (BEA-C) of suffering a major liver-related complication. Note: due to missing values of the different variables, only 59 of the 75 anti-HDV patients were included in this analysis. (b) Receiving operating characteristic (ROC) curves of the BEA score and the three BEA risk categories.
Mentions: After the variable selection was finished, we assigned them points according to their hazard ratio (HR): age older than 40 (HR = 2.1, P = 0.04), Eastern Mediterranean origin (HR = 3.76, P < 0.001), INR above 1.2 (HR = 4.56, P < 0.001), platelet count below 100 000/μL (1 point, HR = 6.65, P < 0.001) or 50 000/μL (2 points, HR = 11.63, P < 0.001), bilirubin above the ULN (HR = 2.21, P = 0.04) and male sex (HR = 2.07, P = 0.08) (Table 2, Fig. 2a). Taken together, in the BEA score, we included factors that reflect the patient's demographics, the presence of portal hypertension, and the liver's protein production and breakdown functions.

Bottom Line: The baseline-event-anticipation score (BEA score) was developed based on variables associated with the development of liver-related clinical complications.Age, region of origin, presence of cirrhosis, albumin, INR, hyperbilirubinemia and thrombocytopenia were all associated with the development of an event in the training cohort.Delta hepatitis is associated with a very severe long-term outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF), Partner Side HepNet Study-House, Hannover, Germany.

Show MeSH
Related in: MedlinePlus